Child Pneumonia: Antibiotics Offer Equal Efficacy

New Study Finds No Clear Winner Among Common Antibiotics for Child Pneumonia

Researchers working in 16 Kenyan hospitals randomized 4393 children with severe pneumonia to one of three antibiotic regimens. By day five, 5.5% to 6.0% of children had died across all groups, with no statistically significant differences in survival rates. The Clinical Information Network (CIN) in Kenya, led by principal investigators Dr. Ambrose Agweyu and Prof. Mike English, organized the trial to answer pressing questions about standard hospital care.

Comparing Three Antibiotic Pathways in a Real-World Setting

The trial addressed a practical dilemma. The World Health Organization (WHO) recommends injectable ampicillin (or benzylpenicillin) with gentamicin as first-line treatment for severe childhood pneumonia. However, many hospitals routinely use more expensive, broader-spectrum antibiotics like ceftriaxone or amoxicillin-clavulanic acid, partly due to concerns about resistance. This study directly compared these three options in children aged 2 to 59 months.

Children were randomly assigned to receive benzylpenicillin plus gentamicin (the current standard), ceftriaxone, or amoxicillin-clavulanic acid. The primary goal was to measure death from any cause by day five. Secondary outcomes included treatment failure by day five and later mortality.

Death rates were closely matched: 6.0% for benzylpenicillin-gentamicin, 5.6% for amoxicillin-clavulanic acid, and 5.5% for ceftriaxone. After statistical adjustment, the risk ratios showed no meaningful difference in survival between the groups. This pattern held for the secondary outcomes measured.

Supportive Care: Tube Feeding Versus Intravenous Fluids

A second, smaller part of the trial examined a common supportive care decision. Children with severe pneumonia who cannot eat or drink adequately need help with hydration and nutrition. Doctors often choose between placing a nasogastric tube or giving intravenous (IV) fluids. This study randomly assigned 1064 eligible children to one of these two methods.

The results showed no significant difference in safety or efficacy. By day five, 5.7% of children receiving nasogastric tube feeding had died, compared to 6.7% of those receiving IV fluids. The adjusted analysis concluded the risk was similar. The rates of other safety events, like aspiration or fluid overload, were also not meaningfully different between the groups.

Implications for Guidelines and Hospital Practice

For health policymakers and pediatricians, the antibiotic findings are significant. Benzylpenicillin plus gentamicin is generally cheaper and more targeted than the broader-spectrum alternatives. This study, conducted in a setting with high pneumococcal vaccine coverage, provides evidence that this older regimen can still be effective. Widespread use of this combination could preserve the effectiveness of more powerful antibiotics for other infections and reduce drug costs.

The supportive care result offers practical flexibility. In resource-limited hospitals where IV supplies and nursing care are strained, nasogastric tube feeding appears to be a safe and equivalent option for many children. This can help clinicians make decisions based on available resources and a child’s specific condition.

Parents should know these findings relate to severe, hospitalized pneumonia. The study does not change advice for milder cases managed at home. The researchers, including Dr. Samuel Akech and Prof. Grace Irimu, emphasize that all treatments were administered in a hospital with careful monitoring.

This preprint has important limitations. The study was conducted only in Kenya, so results may not apply directly to regions with different bacterial prevalence or vaccination rates. The open-label design means doctors knew which treatment a child received, which could influence other care decisions. Peer review will examine the analysis and interpretation in detail before the findings can be fully integrated into global guidelines.

Source:
A Pragmatic Trial of Antibiotics and Supportive Care for Severe Pneumonia in Hospitalized Children. (medRxiv preprint, 2026-05-06)